Thermo Fisher Scientific, Symphogen: collaborative agreement
Thermo Fisher Scientific and Symphogen plan to extend their collaboration to provide biopharmaceutical discovery and development laboratories with tools and workflows for efficient characterization of complex therapeutic proteins. The collaboration first started in 2018.
"The extension of our collaborative relationship with Symphogen demonstrates our continued commitment to solve tangible scientific challenges within the biopharmaceutical industry," said Eric Grumbach, director of biopharma and pharma business, chromatography, and mass spectrometry with Thermo Fisher. "Further investment in this collaboration enables critical insights that feed directly into the development of new analytical tools, providing meaningful impact to the characterization of complex biotherapeutics."